AcelRx Pharmaceuticals Inc.’s bid to bring its acute pain treatment Zalviso to the U.S. market has been tripped up by issues with the device for the sufentanil sublingual tablet system.
FDA has issued a “complete response” letter on AcelRx’s 505(b)(2) NDA for management of moderate-to-severe pain in hospitalized patients, the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?